| Jun 11 |
Donanemab approval would fuel growth of amyloid-blocking Alzheimer’s drugs, analysts say
|
| Jun 11 |
Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
|
| Jun 10 |
FDA panel votes unanimously for Eli Lilly's Alzheimer's treatment
|
| Jun 10 |
Biogen, Eisai get January 2025 FDA action date for monthly Leqembi
|
| Jun 10 |
Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
|
| Jun 10 |
Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
|
| Jun 9 |
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
|
| Jun 8 |
Lilly's donanemab, remternetug set to dominate Alzheimer's treatment by 2030
|
| Jun 7 |
Why Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report?
|
| Jun 6 |
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
|
